About Juvena Therapeutics
Juvena Therapeutics is a company based in San Mateo (United States) founded in 2017 by Jeremy O'Connell and Hanadie Yousef. Juvena Therapeutics has raised $75.81 million across 4 funding rounds from investors including HHS, Mubadala and Plum Alley Investments. Juvena Therapeutics offers products and services including JUV-161 and Secreted Proteins Platform. Juvena Therapeutics operates in a competitive market with competitors including Adocia, Altimmune, Carmot, BioAge Labs and Fractyl, among others.
- Headquarter San Mateo, United States
- Founders Jeremy O'Connell, Hanadie Yousef
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Juvena Therapeutics Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$75.81 M (USD)
in 4 rounds
-
Latest Funding Round
$30.49 M (USD), Series A
Jun 27, 2025
-
Investors
HHS
& 13 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Juvena Therapeutics
Juvena Therapeutics offers a comprehensive portfolio of products and services, including JUV-161 and Secreted Proteins Platform.
Biologic targeting Myotonic Dystrophy Type 1 for muscle degeneration repair
Tool for mapping and engineering proteins to treat metabolic diseases
People of Juvena Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Juvena Therapeutics
Juvena Therapeutics has successfully raised a total of $75.81M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $30.49 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Juvena Therapeutics
Juvena Therapeutics has secured backing from 14 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include HHS, Mubadala and Plum Alley Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Horizons Ventures is focused on investing in deep science and technology.
|
Locked | Locked | Locked | |
|
Bison Ventures is focused on investing in frontier technology companies.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Juvena Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Juvena Therapeutics
Investment portfolio details for Juvena Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Juvena Therapeutics
Detailed financials for Juvena Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Juvena Therapeutics Comparisons
Peer comparison for Juvena Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Juvena Therapeutics
Juvena Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adocia, Altimmune, Carmot, BioAge Labs and Fractyl, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| Locked | Locked | Locked |
Disease-modifying therapies for metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Bioinformatics platform is provided for biomarkers and drug discovery.
|
|
| Locked | Locked | Locked |
Endoscopic procedures for type-2 diabetes treatment are developed.
|
|
| Locked | Locked | Locked |
Peptide-based therapies for obesity and cardiometabolic disorders are developed.
|
Detailed competitors of Juvena Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Juvena Therapeutics
Complete news archive for Juvena Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Juvena Therapeutics
Juvena Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Juvena Therapeutics is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Hanadie Yousef is the current CEO of Juvena Therapeutics. They have also founded this company.
Juvena Therapeutics is a funded company, having raised a total of $75.81M across 4 funding rounds to date.
Juvena Therapeutics was founded in 2017 in San Mateo, United States, within the biotechnology sector. Protein-based therapeutics are developed by the company to promote tissue generation in the elderly, with a focus on sarcopenia and muscle regeneration. A discovery platform is utilized for screening restored muscle function, which can be extended to other tissue types. A protein cocktail has been created to enhance healing, regeneration, and appearance in aged muscle.
Juvena Therapeutics's top competitors include Adocia, BioAge Labs and Fractyl.
Juvena Therapeutics offers JUV-161 and Secreted Proteins Platform.
Juvena Therapeutics has 14 investors. Key investors include HHS, Mubadala, Plum Alley Investments, Horizons Ventures, and Bison Ventures.